Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 8, Issue 2, 2007, Pages 81-84

  Dechend, Ralf ^a   Shagdarsuren, Erdenechimeg ^a,c   Gratze, Petra ^a   Fiebeler, Anette ^a   Pilz, Bernhard ^a   Meiners, Silke ^a   Derer, Wolfgang ^a   Feldman, David L ^c   Webb, Randy ^c   Muller, Dominik N ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Albuminuria; Angiotensin II; Cardiac damage; Inflammation; Renin inhibitor

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; CD86 ANTIGEN; LOSARTAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RENIN; RENIN INHIBITOR;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENZYME INHIBITION; HEART LEFT VENTRICLE WALL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY FIBROSIS; LOW DRUG DOSE; MACROPHAGE; MONOCYTE; MORTALITY; NONHUMAN; ORGAN INJURY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TRANSGENIC RAT;

AMIDES; ANGIOTENSINOGEN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIHYPERTENSIVE AGENTS; FUMARATES; HUMANS; HYPERTENSION; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 34547972201     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2007.008     Document Type: Article

References (10)

1. Ganten D, Wagner J, Zeh K et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 1992; 89:7806-10.
2. Mervaala E, Muller DN, Schmidt F et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000;35:587-94.
3. Muller DN, Shagdarsuren E, Park JK et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 2002;161:1679-93.
4. Pilz B, Shagdarsuren E, Wellner M et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76.
5. Shagdarsuren E, Wellner M, Braesen JH et al. Complement activation in angiotensin II-induced organ damage. Circ Res 2005; 97:716-24.
6. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999; 12:205S-213S.
7. Mervaala EMA, Muller DN, Schmidt F et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000;35:587-94.
8. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004;44:595-601.
9. Ichihara A, Hayashi M, Kaneshiro Y et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114;1128-35.
10. Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27.